Impact of conditioning regimen on peripheral blood hematopoietic cell transplant

Table 2 Patient characteristics for each of four conditioning regimen groups, n (%)

	MA-noTBI (n = 38)	MA+TBI (n = 51)	RIC-noTBI (n = 118)	RIC+TBI (n = 40)	P
Age at BMT					< 0.0001
Median-years (range)	47 (26-58)	36 (19-51)	54 (23-73)	61 (23-71)
< 40	6 (16)	29 (57)	22 (19)	3 (8)
≥ 40	32 (84)	22 (43)	96 (81)	37 (93)
Gender					NS
Female	21 (55)	19 (37)	45 (38)	22 (55)
Male	17 (45)	32 (63)	73 (62)	18 (45)
Diagnosis					< 0.0001
ALL	0	20 (39)	7 (6)	6 (15)
AML	11 (29)	28 (55)	58 (49)	14 (35)
CML	7 (18)	1 (2)	3 (3)	1 (3)
MDS/MPD	11 (29)	1 (2)	23 (19)	10 (25)
NHL/CLL/PLL	8 (21)	1 (2)	25 (21)	8 (20)
Other	1 (3)	0	2 (2)	1 (3)
Karnofsky Performance Status					0.03
≤ 70	8 (21)	8 (16)	35 (30)	13 (33)
80	13 (34)	15 (29)	51 (43)	14 (35)
≥ 90	17 (45)	28 (55)	32 (27)	13 (33)
BMT Regimen					< 0.0001
BuCy	36 (95)	0	0	0
CyTBI	0	47 (92)	0	0
FluCy	0	0	12 (10)	0
FluMel	0	0	102 (86)	0
FluMelTBI	0	0	0	40 (100)
Other	2 (5)	4 (8)	4 (3)	0
Sex Match					NS
Matched	24 (63)	30 (59)	70 (59)	27 (68)
Mismatched	14 (37)	21 (41)	48 (41)	13 (33)
Donor					< 0.0001
HLA Matched Related	33 (87)	31 (61)	54 (46)	17 (43)
HLA Matched Unrelated	5 (13)	20 (39)	64 (54)	23 (58)
GvHD Prophylaxis					< 0.0001
TacMtx	18 (47)	35 (69)	33 (28)	0
TacMMF	4 (11)	2 (4)	18 (15)	0
TacmMtxMMF	15 (39)	7 (14)	64 (54)	40 (100)
Single Agent	1 (3)	7 (14)	3 (3)	0
CMV Status					NS
R+D+	6 (16)	8 (16)	28 (24)	9 (23)
R+D-	14 (37)	12 (24)	35 (30)	12 (30)
R-D+	0	8 (16)	18 (15)	4 (10)
R-D-	18 (47)	23 (45)	37 (31)	15 (38)
BMI kg/m2					NS
Normal (< 30)	15 (39)	25 (49)	34 (29)	13 (33)
Overweight (25-< 30)	12 (32)	14 (27)	40 (34)	15 (38)
Obese (≥ 30-< 35)	7 (18)	7 (14)	28 (24)	7 (18)
Morbid (≥ 35)	4 (11)	5 (10)	16 (14)	5 (13)

MA: Myeloablative; TBI: Total body irradiation; RIC: Reduced intensity conditioning; ALL: Acute lymphoid leukemia; AML: Acute myeloid leukemia; CML: Chronic myeloid leukemia; MDS: Myelodysplastic syndrome; MPD: Myeloproliferative disorder; NHL: Non-Hodgkin lymphoma; CLL: Chronic lymphocytic leukemia; PLL: Prolymphocytic leukemia; Bu: Busulfan; Cy: Cyclophosphamide; Flu: Fludarabine; Mel: Melphalan; Tac: Tacrolimus; Mtx: Methotrexate; mMt: Micro dose methotrexate; MMF: Mycophenylate mofetil ; R: Recipient; D: Donor; BMI: Body mass index; NS: Not significant (P > 0.05).